ReACT Therapeutics’ Post

🎬 CHECK OUT OUR NEW VIDEO! 🎬 We are on a mission to address the urgent needs of patients facing treatment failure by targeting Multi-Drug Resistance (MDR) phenomena in oncology. Clinical data reveals that a staggering 90% of deaths during anticancer treatment are linked to MDR. That's why we are specifically focusing on combating the efflux of anticancer drugs through the Breast Cancer Resistance Protein (BCRP), which is expressed in various cancer types, including 9 out of the 10 most prevalent cancers worldwide. It's a critical challenge that currently lacks an effective solution. After over 15 years of tireless academic research, we've developed highly innovative BCRP inhibitors that are protected by robust intellectual property rights in key global markets. Our lead molecule, ValOMé, represents the cutting-edge fifth generation of BCRP inhibitors, surpassing previous versions in terms of safety, selectivity, and efficacy.  But that's not all - ValOMé has the potential to be combined with existing and future anticancer drugs, revolutionizing treatment options for patients. In fact, we have identified 40 anticancer drugs effluxed by BCRP, utilized for 14 indications across chemotherapy, targeted therapy, hormone therapy, and even antibody-drug conjugates. The potential impact of our technology is immense. By leveraging our novel chemical entities' remarkable selectivity for BCRP, ReACT Therapeutics has the power to significantly improve remission rates and enhance the quality of life for countless patients. Our initial preclinical developments have already demonstrated the safety and efficacy of ValOMé. Now, we're thrilled to embark on the next phase of our journey. Over the next three years, we're fully committed to completing the preclinical phase and regulatory affairs, paving the way for groundbreaking clinical trials ➡️ Join us on this exhilarating path as we revolutionize the fight against MDR in oncology. Together, we can make a resounding difference and reshape the future of cancer treatment. Stay tuned for more updates as we forge ahead towards our shared vision of better health for all. Bpifrance, Linksium, Lyonbiopôle, Cancéropôle Lyon Auvergne-Rhône-Alpes, CHU Grenoble Alpes, Centre Léon Bérard, Hospices Civils de Lyon, Université Grenoble Alpes, CNRS - Centre national de la recherche scientifique, Région Auvergne-Rhône-Alpes #ReACTTherapeutics #BiotechStartup #Oncology #MDR #Innovation #CancerTreatment #Research #ClinicalTrials